Oropfen (Flurbiprofen)

Flurbiprofen, the active ingredient in Oropfen, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral tablet for oral use. It is employed to relieve pain and inflammation in conditions such as rheumatoid arthritis, osteoarthritis and acute musculoskeletal disorders, providing clinicians with a short‑term analgesic option and is indicated for short‑term therapy under medical supervision.

GNH USA supplies Oropfen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with established quality systems and regulatory approvals across the European market.

Flurbiprofen acts as an NSAID to reduce inflammation and pain in several musculoskeletal disorders. - Rheumatoid arthritis: reduces joint inflammation and pain. - Osteoarthritis: alleviates chronic joint discomfort. - Acute musculoskeletal pain: provides short‑term analgesia.

Adverse reactions may occur with flurbiprofen therapy.

Common Side Effects: - Dyspepsia: stomach discomfort or indigestion. - Nausea: feeling of sickness or urge to vomit. - Headache: mild to moderate head pain. - Dizziness: sensation of light‑headedness. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding: potentially life‑threatening. - Renal impairment: reduced kidney function. - Hepatotoxicity: liver injury. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Anaphylaxis: acute allergic reaction requiring emergency care.

Before prescribing Oropfen, clinicians should consider several safety factors. - Assess renal function: monitor creatinine in patients with kidney disease. - Evaluate cardiovascular risk: avoid in uncontrolled hypertension or heart failure. - Review gastrointestinal history: use cautiously in patients with ulcer disease. - Avoid in late pregnancy: contraindicated during the third trimester. - Store at room temperature: keep in the original pack, protect from moisture and light.

Flurbiprofen can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity. - Selective serotonin reuptake inhibitors (SSRIs): heightened hemorrhage risk.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible decline in renal function. - Diuretics: may reduce antihypertensive efficacy. - Lithium: NSAIDs may raise lithium serum levels.